| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director | COO and President +3 more
2 companies
Jennifer Buell is Chief Executive Officer at INKT, with reported holdings spanning 2 companies. Jennifer Buell's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $932K at current prices.
Jennifer Buell's largest disclosed position is in INKT as Chief Executive Officer, worth about $801K. The INKT filings lean toward selling, a net 6,938 shares.
Jennifer Buell has 35 Form 4 filings on record from September 2017 to October 2026, across 3 companies: Chief Executive Officer at MiNK Therapeutics (INKT), 2022–2026; Agenus (AGEN), 2017–2026; Director at Protagenic Therapeutics, Inc.\new (PTIX), 2020–2024.
The 46 reported transactions were 21 option or other derivative awards, 16 stock awards, 4 tax withholdings and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $85K.
The largest open-market sale was 6,938 shares of INKT at an average $10.56 on October 12, 2026, about $73K.